FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3116403304> ?p ?o ?g. }

• W3116403304 abstract "Abstract Background : The treatment of patients with COVID-19 included supportive care to relief the symptoms mainly. Although WHO mentioned there is not any effective treatments for COVID-19, but there is some reporting about the use of some antiviral drugs. The aim of current study is to determine the effect of Arbidol (ARB) on COVID-19 disease. Methods : Using an open label randomized controlled trial, effectiveness of ARB on COVID-19 disease was conducted in a teaching hospital. One hundred eligible patients with diagnosis of Covid-19 recruited in the study and assigned randomly to two groups of either Hydroxychloroquine followed by Kaletra (Lopinavir-ritonavir) or Hydroxychloroquine followed by ARB. The primary outcome was hospitalization duration and clinical improvement 7 days after admission. The criteria of improvement were relief of cough, dyspnea and fever. Time to relieving fever was assessed across two groups too. Without any drop out, 100 patients were entered to final analysis with significant level of 0.05. Results : The mean age of the patients was 56.6 (17.8) and 56.2 (14.8) in ARB and Kaletra groups respectively. Majority of patients were male across two groups (66% and 54%). The duration of hospitalization in ARB group was less than Kaletra arm significantly (7.2 versus 9.6 days; P=0.02). Time to relief fever was almost similar across two groups (2.7 versus 3.1 days in ARB and Kaletra arms respectively). Peripheral oxygen saturation rate was different after seven days of admission across two groups significantly (94% versus 92% in ARB and Kaletra groups respectively) (P=0.02). Based on multiple linear regression analysis, IHD, Na level and oxygen saturation at the time of admission and type of therapy were the independent adjusted variables that determined the duration of hospitalization in patients with COVID-19. Conclusion : Our findings showed that Arbidol, compared to Kaletra, significantly contributes to clinical and laboratory improvements, including peripheral oxygen saturation, requiring ICU admissions, duration of hospitalization, chest CT involvements, WBC, and ESR. We suggest further studies on ARB using larger sample size and multicenter design. Trial registration : IRCT20180725040596N2 on 18 April 2020." @default.
• W3116403304 created "2021-01-05" @default.
• W3116403304 creator A5023747534 @default.
• W3116403304 creator A5043637064 @default.
• W3116403304 creator A5049018082 @default.
• W3116403304 creator A5052235624 @default.
• W3116403304 creator A5055225998 @default.
• W3116403304 creator A5062598321 @default.
• W3116403304 creator A5072858562 @default.
• W3116403304 creator A5081907933 @default.
• W3116403304 creator A5082233866 @default.
• W3116403304 date "2020-09-16" @default.
• W3116403304 modified "2023-09-27" @default.
• W3116403304 title "Effect of Arbidol on COVID-19: A Randomized Controlled Trial" @default.
• W3116403304 doi "https://doi.org/10.21203/rs.3.rs-78316/v1" @default.
• W3116403304 hasPublicationYear "2020" @default.
• W3116403304 type Work @default.
• W3116403304 sameAs 3116403304 @default.
• W3116403304 citedByCount "4" @default.
• W3116403304 countsByYear W31164033042020 @default.
• W3116403304 countsByYear W31164033042021 @default.
• W3116403304 countsByYear W31164033042023 @default.
• W3116403304 crossrefType "posted-content" @default.
• W3116403304 hasAuthorship W3116403304A5023747534 @default.
• W3116403304 hasAuthorship W3116403304A5043637064 @default.
• W3116403304 hasAuthorship W3116403304A5049018082 @default.
• W3116403304 hasAuthorship W3116403304A5052235624 @default.
• W3116403304 hasAuthorship W3116403304A5055225998 @default.
• W3116403304 hasAuthorship W3116403304A5062598321 @default.
• W3116403304 hasAuthorship W3116403304A5072858562 @default.
• W3116403304 hasAuthorship W3116403304A5081907933 @default.
• W3116403304 hasAuthorship W3116403304A5082233866 @default.
• W3116403304 hasBestOaLocation W31164033041 @default.
• W3116403304 hasConcept C126322002 @default.
• W3116403304 hasConcept C142462285 @default.
• W3116403304 hasConcept C168563851 @default.
• W3116403304 hasConcept C203014093 @default.
• W3116403304 hasConcept C2777182164 @default.
• W3116403304 hasConcept C2779123688 @default.
• W3116403304 hasConcept C2779134260 @default.
• W3116403304 hasConcept C2779298103 @default.
• W3116403304 hasConcept C2781392899 @default.
• W3116403304 hasConcept C2993143319 @default.
• W3116403304 hasConcept C3008058167 @default.
• W3116403304 hasConcept C3013748606 @default.
• W3116403304 hasConcept C42219234 @default.
• W3116403304 hasConcept C524204448 @default.
• W3116403304 hasConcept C71924100 @default.
• W3116403304 hasConceptScore W3116403304C126322002 @default.
• W3116403304 hasConceptScore W3116403304C142462285 @default.
• W3116403304 hasConceptScore W3116403304C168563851 @default.
• W3116403304 hasConceptScore W3116403304C203014093 @default.
• W3116403304 hasConceptScore W3116403304C2777182164 @default.
• W3116403304 hasConceptScore W3116403304C2779123688 @default.
• W3116403304 hasConceptScore W3116403304C2779134260 @default.
• W3116403304 hasConceptScore W3116403304C2779298103 @default.
• W3116403304 hasConceptScore W3116403304C2781392899 @default.
• W3116403304 hasConceptScore W3116403304C2993143319 @default.
• W3116403304 hasConceptScore W3116403304C3008058167 @default.
• W3116403304 hasConceptScore W3116403304C3013748606 @default.
• W3116403304 hasConceptScore W3116403304C42219234 @default.
• W3116403304 hasConceptScore W3116403304C524204448 @default.
• W3116403304 hasConceptScore W3116403304C71924100 @default.
• W3116403304 hasLocation W31164033041 @default.
• W3116403304 hasOpenAccess W3116403304 @default.
• W3116403304 hasPrimaryLocation W31164033041 @default.
• W3116403304 hasRelatedWork W3035043675 @default.
• W3116403304 hasRelatedWork W3035595114 @default.
• W3116403304 hasRelatedWork W3087721407 @default.
• W3116403304 hasRelatedWork W3116141061 @default.
• W3116403304 hasRelatedWork W3118340001 @default.
• W3116403304 hasRelatedWork W3131292284 @default.
• W3116403304 hasRelatedWork W3188373213 @default.
• W3116403304 hasRelatedWork W3197040286 @default.
• W3116403304 hasRelatedWork W4226115566 @default.
• W3116403304 hasRelatedWork W4229334037 @default.
• W3116403304 isParatext "false" @default.
• W3116403304 isRetracted "false" @default.
• W3116403304 magId "3116403304" @default.
• W3116403304 workType "article" @default.